CLB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CLB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-28), Core Laboratories's current share price is $17.92. Core Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2023 was $18.49. Core Laboratories's Cyclically Adjusted PS Ratio for today is 0.97.
The historical rank and industry rank for Core Laboratories's Cyclically Adjusted PS Ratio or its related term are showing as below:
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Core Laboratories's adjusted revenue per share data for the three months ended in Mar. 2023 was $2.703. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $18.49 for the trailing ten years ended in Mar. 2023.
The historical data trend for Core Laboratories's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Core Laboratories Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 1.64 | 1.05 | 0.68 | 1.07 | 1.19 |
For the Oil & Gas Equipment & Services subindustry, Core Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Oil & Gas industry and Energy sector, Core Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Core Laboratories's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Core Laboratories's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 17.92 | / | 18.49 | |
= | 0.97 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Core Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2023 is calculated as:
For example, Core Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2023 (Change) | * | Current CPI (Mar. 2023) |
= | 2.703 | / | 124.7200 | * | 124.7200 | |
= | 2.703 |
Current CPI (Mar. 2023) = 124.7200.
Core Laboratories Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201306 | 5.705 | 98.320 | 7.237 |
201309 | 5.961 | 99.080 | 7.504 |
201312 | 6.069 | 98.360 | 7.695 |
201403 | 5.819 | 99.390 | 7.302 |
201406 | 5.958 | 99.240 | 7.488 |
201409 | 6.222 | 99.960 | 7.763 |
201412 | 6.342 | 99.050 | 7.986 |
201503 | 4.915 | 99.750 | 6.145 |
201506 | 4.746 | 100.230 | 5.906 |
201509 | 4.621 | 100.500 | 5.735 |
201512 | 4.298 | 99.730 | 5.375 |
201603 | 3.614 | 100.310 | 4.493 |
201606 | 3.403 | 100.260 | 4.233 |
201609 | 3.237 | 100.570 | 4.014 |
201612 | 3.272 | 100.710 | 4.052 |
201703 | 3.531 | 101.440 | 4.341 |
201706 | 3.565 | 101.370 | 4.386 |
201709 | 3.674 | 102.030 | 4.491 |
201712 | 3.853 | 101.970 | 4.713 |
201803 | 3.824 | 102.470 | 4.654 |
201806 | 3.944 | 103.100 | 4.771 |
201809 | 4.085 | 103.950 | 4.901 |
201812 | 3.916 | 103.970 | 4.698 |
201903 | 3.782 | 105.370 | 4.477 |
201906 | 3.772 | 105.840 | 4.445 |
201909 | 3.873 | 106.700 | 4.527 |
201912 | 3.533 | 106.800 | 4.126 |
202003 | 3.429 | 106.850 | 4.002 |
202006 | 2.603 | 107.510 | 3.020 |
202009 | 2.347 | 107.880 | 2.713 |
202012 | 2.556 | 107.850 | 2.956 |
202103 | 2.358 | 108.870 | 2.701 |
202106 | 2.521 | 109.670 | 2.867 |
202109 | 2.504 | 110.790 | 2.819 |
202112 | 2.705 | 114.010 | 2.959 |
202203 | 2.490 | 119.460 | 2.600 |
202206 | 2.564 | 119.050 | 2.686 |
202209 | 2.679 | 126.890 | 2.633 |
202212 | 2.751 | 124.940 | 2.746 |
202303 | 2.703 | 124.720 | 2.703 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Core Laboratories's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Katherine Murray | director | 6316 WINDFERN ROAD, HOUSTON TX 77040 |
Mark Damian Tattoli | officer: SVP, Gen Counsel & Secretary | C/O CORE LABORATORIES LP, 6316 WINDFERN ROAD, HOUSTON TX 77040 |
Kwaku Temeng | director | C/O CORE LABORATORIES LP, 2216 SHERIDAN STREET, HOUSTON TX 77002 |
Gwendolyn Schreffler | officer: SVP | C/O CORE LABORATORIES LP, 6316 WINDFERN ROAD, HOUSTON TX 77040 |
Harvey Robert Klingensmith | director | P.O. BOX 131144, HOUSTON TX 77219-1114 |
Van Dijken Eeuwijk Monique | director | P.O. BOX 129, BILTHOVEN P7 3720 AC |
Jan Willem Sodderland | director | DUINDISTEL 89, NOORDWIJK P7 2202 DE |
Goldman Sachs Group Inc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Lawrence Bruno | officer: President | 6316 WINDFERN ROAD, HOUSTON TX 77040 |
Mark F Elvig | officer: VP, Counsel & Secretary | 6316 WINDFERN, HOUSTON TX 77040 |
Gregory Barry Barnett | director | 853 MILWAUKEE STREET, DENVER CO 80206 |
Kevin Daniels | officer: CAO & Treasurer | 6316 WINDFERN ROAD, HOUSTON TX 77040 |
Michael Straughen | director | 68 RUBISLAW DEN NORTH, ABERDEEN X0 AB15 4AN |
Martha Z. Carnes | director | 6316 WINDFERN ROAD, HOUSTON TX 77040 |
From GuruFocus
By PRNewswire PRNewswire • 06-29-2022
By PRNewswire PRNewswire • 07-08-2022
By PRNewswire PRNewswire • 12-29-2020
By PRNewswire • 06-27-2023
By PRNewswire PRNewswire • 01-16-2021
By Sydnee Gatewood • 10-20-2022
By GuruFocus Research GuruFocus Editor • 07-30-2021
By PRNewswire PRNewswire • 07-14-2021
By PRNewswire PRNewswire • 06-19-2022
By PRNewswire PRNewswire • 03-27-2023